Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

• المؤلفون الرئيسيون: M. Rizzo (مؤلف), S. Pontarollo (مؤلف), F. Tiso (مؤلف), R. Montisci (مؤلف), H. Marotta (مؤلف), F. Tona (مؤلف), S. Iliceto (مؤلف), F. Cozzi (مؤلف)
• التنسيق: كتاب
• منشور في: PAGEPress Publications, 2011-09-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Objective: Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue diseases (CTD), with a negative impact on patients survival. Bosentan, a receptor antagonist of endothelin, has been proved effective for the treatment of PAH. The aim of this study was to evaluat...